Siegfried Oberndorfer was born in Munich, Germany, in 1876, studied medicine at the University of Munich, and became the youngest Jewish physician to be appointed to its faculty (1907). His unique observations regarding multiple small-intestinal tumors were presented at the German Pathological Society convention (Dresden, Germany, September 1907), where he coined the term karzinoide and published it in December of the same year. Twenty-two years later (in 1929), he amended this report and suggested that carcinoid tumors might also exhibit malignant features and metastasize. The rise of Nazism led to the termination of his position in 1933, and he “emigrated” to Turkey to serve as the chair of anatomical pathology at the University of Istanbul, Istanbul, Turkey, where he remained until his death in 1944. This exploration of his life and times seeks to give Oberndorfer his well-deserved place in the pantheon of pathology and memorialize his unique observations that led to the discovery of the carcinoid tumor.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
In September 1907, Siegfried Oberndorfer presented his seminal work on carcinoid tumors at the German Pathological Society meeting in Dresden, Germany, and 3 months later it was published in the Frankfurt Journal of Pathology (frontispiece, top right). He described 6 cases of ileal tumors that grew extremely slowly and did not appear to metastasize. On recognizing that these tumors represented a novel disease entity, he ascribed a name to describe the nature of these tumors, karzinoide, or carcinomalike.
A timeline of the evolution of the diagnosis and management of carcinoid tumor disease. WHO indicates World Health Organization; APUD, amine precursor uptake and decarboxylation; 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, 5-hydroxytryptamine; EC, enterochromaffin; ECL, enterochromaffin-like.
Theodor Langhans (1839-1915) (top left) published the first report (1867) of a carcinoid tumor (frontispiece, bottom left). Otto Lubarsch (1860-1933) (bottom right) provided the first detailed pathological description (top right) of carcinoid tumors (1888).
Pierre Masson (top right) and Andre Gosset (top left) demonstrated the argentaffin staining properties of carcinoid tumors (frontispiece, top) and proposed that the enterochromaffin cells in the gut formed a diffuse endocrine organ. The first description of this diffuse neuroendocrine system was provided in 1938 by Friedrich Feyrter (bottom right).
Siegfried Oberndorfer was responsible for the planning and development of the new Pathological Institute of the Munich-Schwabing Hospital, which he described in 1912 (frontispiece, bottom; floor plan, background). From 1911 to 1933, he served as professor and chair of the Pathological Institute, and in 1915, he served Germany during World War I as an army pathologist (center).
In 1933, Siegfried Oberndorfer's career was summarily terminated when the National Socialist German Workers' Party orchestrated the boycott of all Jewish physicians. Kemal Pascha (“Atatürk”) (top center) retained Albert Malche, the former Swiss minister of education, to assist in the reformation of the Turkish University system. To this end, Malche undertook the recruitment of the academic elite purged from German universities; by the close of the war, the University of Istanbul was considered the best German university in the world. In 1933, Malche sent an invitation (top left) to Oberndorfer to serve as chair of general and experimental pathology at the University of Istanbul, where he initially delivered his lectures in German with a translator by his side (bottom right).
Siegfried Oberndorfer (top right) died in 1944 at the age of 67 years and was buried at the Sisli cemetery in Istanbul (bottom left). The original autopsy report (background) indicated the cause of death to be a mediastinal mass; in 2004, reexamination of the original tumor specimen at the Yale University School of Medicine confirmed the tumor to be a thymoma (center).
Thank you for submitting a comment on this article. It will be reviewed by JAMA Surgery editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 8
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.